# Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants

> **NCT01082692** · PHASE1 · COMPLETED · sponsor: **Inovio Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- HIV-1 Infection
- HIV Infections

## Interventions

- **BIOLOGICAL:** PENNVAX-B

## Key facts

- **NCT ID:** NCT01082692
- **Lead sponsor:** Inovio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2012-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01082692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01082692, "Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01082692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*